Related Experiment Video
Updated: Nov 2, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
Veronika Ecker1,2, Martina Stumpf1,2, Lisa Brandmeier1,2
1Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany.
None:
Current therapeutic approaches for chronic lymphocytic leukemia (CLL) focus on the suppression of oncogenic kinase signaling. Here, we test the hypothesis that targeted hyperactivation of the phosphatidylinositol-3-phosphate/AKT (PI3K/AKT)-signaling pathway may be leveraged to trigger CLL cell death. Though counterintuitive, our data show that genetic hyperactivation of PI3K/AKT-signaling or blocking the activity of the inhibitory phosphatase SH2-containing-inositol-5'-phosphatase-1 (SHIP1) induces acute cell death in CLL cells. Our mechanistic studies reveal that increased AKT activity upon inhibition of SHIP1 leads to increased mitochondrial respiration and causes excessive accumulation of reactive oxygen species (ROS), resulting in cell death in CLL with immunogenic features. Our results demonstrate that CLL cells critically depend on mechanisms to fine-tune PI3K/AKT activity, allowing sustained proliferation and survival but avoid ROS-induced cell death and suggest transient SHIP1-inhibition as an unexpectedly promising concept for CLL therapy.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
The Intrinsic Apoptotic Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

